© 1999 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
Antipsychotics: Past and Future National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998
Assistant Professor, Department of Psychiatry, University of North Carolina Chapel Hill, NC
Professor, Department of Psychiatry, University of North Carolina Chapel Hill, NC
Chief of Adult and Geriatric Treatment and Preventive Intervention Research Branch (AGTPIRB), National Institute of Mental Health Rockville, MD
Head of Special Projects Programs, AGTPIRB and Editor-in-Chief of the Schizophrenia Bulletin, National Institute of Mental Health Rockville, MD
Reprint requests should be sent to Dr. K. Dawkins, Dept. of Psychiatry, Campus Box 7160, The University of North Carolina, Chapel Hill, NC 27599-7160
A workshop on "Antipsychotics: Past and Future" was convened by the National Institute of Mental Health (NIMH), Division of Services and Intervention Research (DSIR), on July 14, 1998, to review the results of recent antipsychotic drug research, discuss current standards of treatment, and identify areas needing further study. There has been a proliferation of new antipsychotic medications and a rapid increase in their clinical utilization. The new atypicals are beginning to supplant the older typical neuroleptic antipsychotics, and the scientific and ethical issues raised by this transition prompted the workshop. Given the apparent, albeit not fully defined, advantages of atypical drugs, particularly their safety profiles, the question is whether more comparisons with typical antipsychotics are warranted and whether clinical trial designs warrant (or would be justified in) the inclusion of typical drugs as standard active comparators. Workshop participants—including clinical researchers, patient advocates, bioethicists, and NIMH staff—discussed the conclusions drawn from current data, ethical issues for subjects in clinical trials, funding for ongoing studies using typical agents, and appropriate comparators for trials using atypical agents.
Keywords: Antipsychotic drugs / atypical antipsychotic drugs / typical antipsychotic drugs / clozapine / risperidone / olanzapine / quetiapine / ziprasidone
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Mallinger, S. G. Fisher, T. Brown, and J. S. Lamberti Racial Disparities in the Use of Second-Generation Antipsychotics for the Treatment of Schizophrenia Psychiatr Serv, January 1, 2006; 57(1): 133 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B Dunn, P. J Candilis, and L. W. Roberts Emerging Empirical Evidence on the Ethics of Schizophrenia Research Schizophr Bull, January 1, 2006; 32(1): 47 - 68. [Abstract] [Full Text] [PDF]
|
|